Paper41300972
Association Between MMR Status and Prognostic Pathological Factors in Endometrioid Endometrial Cancer-A Single-Center Retrospective Study.
Miedziarek C and 6 others. Cancers (Basel), 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Association Between MMR Status and Prognostic Pathological Factors in Endometrioid Endometrial Cancer-A Single-Center Retrospective Study. Papers, record 41300972. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41300972
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Association Between MMR Status and Prognostic Pathological Factors in Endometrioid Endometrial Cancer-A Single-Center Retrospective Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33845554 | Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis. | J Pathol Transl Med | 2021 | https://conductscience.org/library/papers/33845554 | PubMed |
| 2 | 35658479 | TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35658479 | PubMed |
| 3 | 36915143 | The impact of lymphovascular space invasion on survival in early stage low-grade endometrioid endometrial cancer. | Eur J Med Res | 2023 | https://conductscience.org/library/papers/36915143 | PubMed |
| 4 | 37958361 | MLH1 Methylation Testing as an Integral Component of Universal Endometrial Cancer Screening-A Critical Appraisal. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37958361 | PubMed |
| 5 | 30561762 | Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker. | Cancer | 2019 | https://conductscience.org/library/papers/30561762 | PubMed |
| 6 | 38256131 | Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial Cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38256131 | PubMed |
| 7 | 39191994 | Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations. | Virchows Arch | 2024 | https://conductscience.org/library/papers/39191994 | PubMed |
| 8 | 32060377 | Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. | Mod Pathol | 2020 | https://conductscience.org/library/papers/32060377 | PubMed |
| 9 | 32582376 | Clinicopathologic features of endometrial cancer with mismatch repair deficiency. | Ecancermedicalscience | 2020 | https://conductscience.org/library/papers/32582376 | PubMed |
| 10 | 35752743 | p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial. | Mod Pathol | 2022 | https://conductscience.org/library/papers/35752743 | PubMed |
| 11 | 23552806 | Women 50 years or younger with endometrial cancer: the argument for universal mismatch repair screening and potential for targeted therapeutics. | Int J Gynecol Cancer | 2013 | https://conductscience.org/library/papers/23552806 | PubMed |
| 12 | 34431253 | MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas. | J Gynecol Oncol | 2021 | https://conductscience.org/library/papers/34431253 | PubMed |
| 13 | 40361433 | Assessment of p53 in Endometrial Carcinoma Biopsy and Corresponding Hysterectomy Cases in a Real-World Setting: Which Cases Need Molecular Work-Up? | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40361433 | PubMed |
| 14 | 36936577 | Endometrial cancer: molecular classification and future treatments. | BMJ Med | 2022 | https://conductscience.org/library/papers/36936577 | PubMed |
| 15 | 36878570 | Immunotherapy in endometrial cancer. | Int J Gynecol Cancer | 2023 | https://conductscience.org/library/papers/36878570 | PubMed |
| 16 | 39707379 | Prognostic factors and survival outcomes of immunohistochemically detection based-molecular subtypes of endometrial cancer-analysis of 576 clinical cases. | Diagn Pathol | 2024 | https://conductscience.org/library/papers/39707379 | PubMed |
| 17 | 39685500 | The Role of Immunotherapy in MMR-Deficient Endometrial Carcinoma: State of the Art and Future Perspectives. | J Clin Med | 2024 | https://conductscience.org/library/papers/39685500 | PubMed |
| 18 | 38892080 | Molecular Classification of Endometrial Cancer and Its Impact on Therapy Selection. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38892080 | PubMed |
| 19 | 40334309 | Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer. | Gynecol Oncol | 2025 | https://conductscience.org/library/papers/40334309 | PubMed |
| 20 | 24092993 | Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. | Onco Targets Ther | 2013 | https://conductscience.org/library/papers/24092993 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42739604 | Serum Trefoil Factor 3 in Endometrioid Endometrial Carcinoma: Exploratory Diagnostic Value and Association with Lymphovascular Space Invasion. | J Clin Med | 2026 | https://conductscience.org/library/papers/42739604 |
Source PubMed
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EREG | 2069 | PubTator's text mining | https://conductscience.org/library/genes/2069 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| MLH1 | 4292 | PubTator's text mining | https://conductscience.org/library/genes/4292 | NCBI Gene |
| PGR | 5241 | PubTator's text mining | https://conductscience.org/library/genes/5241 | NCBI Gene |
| PMS2 | 5395 | PubTator's text mining | https://conductscience.org/library/genes/5395 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41300972
GET https://conductscience.org/api/papers/v1/41300972/references?page=2